February 17, 2020

Press release

Communiqué from extraordinary general meeting in FluoGuide A/S

FluoGuide A/S (“FluoGuide” or “the Company”) held today an Extraordinary General Meeting (“EGM”). The resolution on a directed issue was resolved.... [Read more]

January 31, 2020

Press release

Extraordinary General Meeting

To the shareholders of FluoGuide A/S Til aktionærerne i FluoGuide A/S (dansk version følger nedenfor) The board of directors hereby convenes... [Read more]

January 29, 2020

Press release

FluoGuide proposes directed share issue to strengthen its ownership and shorten the time to market for FG001

The Board of Directors of FluoGuide A/S (“FluoGuide” or “the Company”) proposes to conduct a directed share issue which can provide... [Read more]

January 9, 2020

Press release

Safety study initiated with FG001

FluoGuide A/S (“FluoGuide”) hereby announces that the first in vivo dosing of FG001 will commence today. This is an important milestone... [Read more]

January 7, 2020

Press release

FluoGuide strengthen its protection on FG001 with the European granting of patent

FluoGuide A/S (“FluoGuide”) is pleased to announce the grant of European patent No. EP3193945 “uPAR targeting peptide for use in peroperative... [Read more]

November 29, 2019

Press release

Interim Report Third Quarter 2019

FluoGuide A/S (“FluoGuide”) today announces its results for the period 01/July/2019 – 30/Sep/2019. The full report is available on the company’s... [Read more]

November 25, 2019

Press release

FluoGuide A/S: Change of report date

FluoGuide A/S will publish its interim report for third quarter 2019 on 29 November 2019. Previously communicated date was 30 November... [Read more]

September 7, 2019

Press release

Presentation of data where FG001 demonstrates dose-depended effectiveness in lightening up glioblastoma in a preclinical model

FluoGuide A/S’s (“FluoGuide”, ticker FLUO) compound FG001 lights up the cancer and has in preclinically studies demonstrated potential to vastly improve... [Read more]

September 6, 2019

Press release

Presentation of data where use of FG001 demonstrates improved surgical outcome in metastatic pancreatic cancer compared to standard surgery using only white light

FluoGuide A/S’s (“FluoGuide”, ticker FLUO) compound FG001 lights up the cancer and has in preclinically studies demonstrated potential to vastly improve... [Read more]